Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc S Raab

Showing results (121-130 of 178) with videos related to

Pageof 18
Sort By:
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Leukemia|May 15, 2025
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Haematologica|September 28, 2019
IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myelomaSantiago Barrio, Umair Munawar, Yuan Xiao Zhu, et al.
Science Immunology|May 3, 2024
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillanceMichael Kilian, Mirco J Friedrich, Kevin Hai-Ning Lu, et al.
Leukemia|April 6, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood Cancer Discovery|February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyJan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Pageof 18

Showing results (121-130 of 178) with videos related to

Sort By:
Pageof 18
Cardio-Oncology (London, England)|July 4, 2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trialLisa B Leypoldt, Linlin Guo, Britta Besemer, et al.
Leukemia|May 15, 2025
Correction: Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Haematologica|September 28, 2019
IKZF1/3 and CRL4<sup>CRBN</sup> E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myelomaSantiago Barrio, Umair Munawar, Yuan Xiao Zhu, et al.
Science Immunology|May 3, 2024
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillanceMichael Kilian, Mirco J Friedrich, Kevin Hai-Ning Lu, et al.
Leukemia|April 6, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibodyMarc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
Leukemia|December 22, 2025
Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myelomaMartin Grözinger, Muriel Schlanke, Jana Gröne, et al.
Blood Cancer Discovery|May 22, 2025
Mutagenic impact and evolutionary influence of chemo-radiotherapy in hematologic malignanciesBenjamin Diamond, Dhanvantri Chahar, Michael D Jain, et al.
Blood Cancer Discovery|February 13, 2026
Clinical scores to predict toxicities and outcomes in patients with multiple myeloma undergoing bispecific T-cell engager therapyJan H Frenking, Christine Riedhammer, Thomas Hielscher, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.
Pageof 18